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Abstract
Background: Reproducibility is a fundamental requirement in scientific experiments. Some recent
publications have claimed that microarrays are unreliable because lists of differentially expressed
genes (DEGs) are not reproducible in similar experiments. Meanwhile, new statistical methods for
identifying DEGs continue to appear in the scientific literature. The resultant variety of existing and
emerging methods exacerbates confusion and continuing debate in the microarray community on
the appropriate choice of methods for identifying reliable DEG lists.
Results: Using the data sets generated by the MicroArray Quality Control (MAQC) project, we
investigated the impact on the reproducibility of DEG lists of a few widely used gene selection
procedures. We present comprehensive results from inter-site comparisons using the same
microarray platform, cross-platform comparisons using multiple microarray platforms, and
comparisons between microarray results and those from TaqMan – the widely regarded "standard"
gene expression platform. Our results demonstrate that (1) previously reported discordance
between DEG lists could simply result from ranking and selecting DEGs solely by statistical
significance (P) derived from widely used simple t-tests; (2) when fold change (FC) is used as the
ranking criterion with a non-stringent P-value cutoff filtering, the DEG lists become much more
reproducible, especially when fewer genes are selected as differentially expressed, as is the case in
most microarray studies; and (3) the instability of short DEG lists solely based on P-value ranking
is an expected mathematical consequence of the high variability of the t-values; the more stringent
the P-value threshold, the less reproducible the DEG list is. These observations are also consistent
with results from extensive simulation calculations.
Conclusion:  We recommend the use of FC-ranking plus a non-stringent P  cutoff as a
straightforward and baseline practice in order to generate more reproducible DEG lists.
Specifically, the P-value cutoff should not be stringent (too small) and FC should be as large as
possible. Our results provide practical guidance to choose the appropriate FC and P-value cutoffs
when selecting a given number of DEGs. The FC criterion enhances reproducibility, whereas the P
criterion balances sensitivity and specificity.
Background
A fundamental step in most microarray experiments is
determining one or more short lists of differentially
expressed genes (DEGs) that distinguish biological condi-
tions, such as disease from health. Challenges regarding
the reliability of microarray results have largely been
founded on the inability of researchers to replicate DEG
lists across highly similar experiments. For example, Tan et
al. [1] found only four common DEGs using an identical
set of RNA samples across three popular commercial plat-
forms. Independent studies by the groups of Ramalho-
Santos [2] and Ivanova [3] of stem cell-specific genes
using the same Affymetrix platform and similar study
design found a disappointing six common DEGs among
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about 200 identified in each study [4]. A comparative neu-
rotoxicological study by Miller et al. [5] using the same set
of RNA samples found only 11 common DEGs among
138 and 425, respectively, from Affymetrix and CodeLink
platforms. All these studies ranked genes by P-value from
simple t-tests, used a P threshold to identify DEG lists, and
applied the concept of the Percentage of Overlapping
Genes (POG), or the Venn diagram, between DEG lists as
the measure of reproducibility.
Criticism of and concerns about microarrays continue to
appear in some of the most prestigious scientific journals
[6-10], leading to a growing negative perception regarding
microarray reproducibility, and hence reliability. How-
ever, in reanalyzing the data set of Tan et al. [1], Shi et al.
[11] found that cross-platform concordance was markedly
improved when either simple fold change (FC) or Signifi-
cance Analysis of Microarrays (SAM) [12] methods were
used to rank order genes before determining DEG lists.
The awareness that microarray reproducibility is sensitive
to how DEGs are identified was, in fact, a major motivator
for the MicroArray Quality Control (MAQC) project
[11,13,14].
Several plausible explanations and solutions have been
proposed to interpret and address the apparent lack of
reproducibility and stability of DEG lists from microarray
studies. Larger sample sizes [15]; novel, microarray-spe-
cific statistical methods [16]; more accurate array annota-
tion information by mapping probe sequences across
platforms [1,17]; eliminating absent call genes from data
analysis [11,18,19]; improving probe design to minimize
cross-hybridization [17]; standardizing manufacturing
processes [1]; and improving data quality by fully stand-
ardizing sample preparation and hybridization proce-
dures are among the suggestions for improvement [20].
The MAQC study [13] was specifically designed to address
these previously identified sources of variability in DEG
lists. Two distinct RNA samples, Stratagene Universal
Human Reference RNA (i.e., MAQC sample A) and
Ambion Human Brain Reference RNA (i.e., MAQC sample
B), with thousands of differentially expressed genes, were
prepared in sufficient quantities and distributed to three
different laboratories for each of the five different com-
mercial whole genome microarray platforms participating
in the study. For each platform, each sample was analyzed
using five technical replicates with standardized proce-
dures for sample processing, hybridization, scanning,
data acquisition, data preprocessing, and data normaliza-
tion at each site. The probe sequence information was
used to generate a stringent mapping of genes across the
different platforms and 906 genes were further analyzed
with TaqMan® assays using the same RNA samples.
In addition to assessing the technical performance of dif-
ferent microarray platforms, the MAQC study also dis-
cussed the idea of using fold-change ranking along with a
non-stringent P-value cutoff for selecting DEGs [13,21].
However, a lot of detailed results have not been formally
published to support the idea [22]. The MAQC project,
while positively received by the community [23-27], also
stimulated criticism from the statistical community about
appropriate ways of identifying DEGs [22,23,27-33].
To help the microarray community better understand the
issue at debate and move forward, in this study, we con-
ducted a careful analysis of these MAQC data sets, along
with numerical simulations and mathematical arguments.
We demonstrate that the reported lack of reproducibility
of DEG lists can be attributed in large part to identifying
DEGs from simple t-tests without consideration of FC.
The finding holds for intra-laboratory, inter-laboratory,
and cross-platform comparisons independent of sample
pairs and normalization methods, and is increasingly
apparent with decreasing number of genes selected.
As a basic procedure for improving reproducibility while
balancing specificity and sensitivity, choosing genes using
a combination of FC-ranking and P threshold was investi-
gated. This joint criterion results in DEG lists with much
higher POG, commensurate with better reproducibility,
than lists generated by t-test P alone, even when selecting
a relatively small numbers of genes. An FC criterion
explicitly incorporates the measured quantity to enhance
reproducibility, whereas a P criterion incorporates control
of sensitivity and specificity. The results increase our con-
fidence in the reproducibility of microarray studies while
supporting a need for caution in the use of inferential sta-
tistics when selecting DEGs. While numerous more
advanced statistical modeling techniques have been pro-
posed and compared for selecting DEGs [16,34,35], the
primary objectives here are to explain that the primary
reason for microarray reproducibility concerns is failure to
include an FC criterion during gene selection, and to rec-
ommend a simple and straightforward approach concur-
rently satisfying statistical and reproducibility
requirements. It should be stressed that robust methods
are needed to meet stringent clinical requirements for
reproducibility, sensitivity and specificity of microarray
applications in, for example, clinical diagnostics and
prognostics.
Results
The POG for a number of gene selection scenarios
employing P and/or FC are compared and a numerical
example (see side box) is provided that shows how the
simple t-test, when sample size is small, results in selec-
tion of different genes purely by chance. While the data
generate from the MAQC samples A and B lack biologicalBMC Bioinformatics 2008, 9(Suppl 9):S10 http://www.biomedcentral.com/1471-2105/9/S9/S10
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variability, the results are supported by the toxicogenomic
data of Guo et al. [21] While P could be computed from
many different statistical methods, for simplicity and con-
sistency, throughout this article P is calculated with the
two-tailed t-test that is widely employed in microarray
data analysis.
Inter-site concordance for the same platform
Figure 1 gives plots of inter-site POG versus the number of
genes selected as differentially expressed. Since there are
three possible inter-site comparisons (S1–S2, S1–S3, and
S2–S3, where S = Site) and six gene selection methods (see
Methods), there are 18 POG lines for each platform. Fig-
ure 1 shows that inter-site reproducibility in terms of POG
heavily depends on the number of chosen differential
genes and the gene ranking criterion: Gene selection using
FC-ranking gives consistently higher POG than P-ranking.
The POG from FC-ranking is near 90% for as few as 20
genes for most platforms, and remains at this high inter-
site concordance level as the number of selected genes
increases. In contrast, the POG from P-ranking is in the
range of 20–40% for as many as 100 genes, and then
asymptotically approaches 90% only after several thou-
sand genes are selected.
Concordance for inter-site comparisons Figure 1
Concordance for inter-site comparisons. Each panel represents the POG results for a commercial platform of inter-site con-
sistency in terms of DEGs between samples B and A. For each of the six gene selection methods, there are three possible 
inter-site comparisons: S1–S2, S1–S3, and S2–S3 (S = Site). Therefore, each panel consists of 18 POG lines that are colored 
based on gene ranking/selection method. Results shown here are based on the entire set of "12,091" genes commonly mapped 
across the microarray platforms without noise (absent call) filtering. POG results are improved when the analyses are per-
formed using the subset of genes that are commonly detectable by the two test sites, as shown in Figure 2. The x-axis repre-
sents the number of selected DEGs, and the y-axis is the percentage (%) of genes common to the two gene lists derived from 
two test sites at a given number of DEGs.BMC Bioinformatics 2008, 9(Suppl 9):S10 http://www.biomedcentral.com/1471-2105/9/S9/S10
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The POG is higher when the analyses are limited to the
genes commonly detected ("Present" in the majority of
replicates for each sample) by both test sites under com-
parison (Figure 2). In addition to a slight increase
(2–3%), the inter-site POG lines after noise filtering are
more stable than those before noise filtering, particularly
for ABI, AG1, and GEH. Furthermore, differences between
the three ILM test sites are further decreased after noise fil-
tering, as seen from the convergence of the POG for
S1–S2, S1–S3, and S2–S3 comparisons. Importantly,
noise filtering does not change either the trend or magni-
tude of the higher POG graphs for FC-ranking compared
with P-ranking.
Inter-site concordance for different FC- and P-ranking cri-
teria were also calculated for other MAQC sample pairs
having much smaller differences than for sample A versus
sample B, and correspondingly lower FC. In general, POG
is much lower for other sample pairs regardless of ranking
method and ranking order varies more greatly, though FC-
ranking methods still consistently give a higher POG than
P-ranking methods. Figure 3 gives the plots of POG for
Sample C versus Sample D, a 3:1 and 1:3 (A:B) mixture,
respectively[13,36], for all inter-site comparisons.
The substantial difference in inter-site POG shown in Fig-
ures 1 and 2 is a direct result of applying different gene
selection methods to the same data sets, and clearly
depicts how perceptions of inter-site reproducibility can
Concordance for inter-site comparisons based on genes commonly detectable by the two test sites compared Figure 2
Concordance for inter-site comparisons based on genes commonly detectable by the two test sites compared. Each panel rep-
resents the POG results for a commercial platform of inter-site consistency in terms of DEGs between samples B and A. For 
each of the six gene selection methods, there are three possible inter-site comparisons: S1–S2, S1–S3, and S2–S3. Therefore, 
each panel consists of 18 POG lines that are colored based on gene ranking/selection method. The x-axis represents the 
number of selected DEGs, and the y-axis is the percentage (%) of genes common to the two gene lists derived from two test 
sites at a given number of DEGs.BMC Bioinformatics 2008, 9(Suppl 9):S10 http://www.biomedcentral.com/1471-2105/9/S9/S10
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be affected for any microarray platform. While the empha-
sis here is on reproducibility in terms of POG, in practice,
this criterion must be balanced against other desirable
characteristics of gene lists, such as specificity and sensitiv-
ity (when the truth is binary) or mean squared error
(when the truth is continuous), considerations that that
are discussed further in later sections.
Cross-platform concordance
Figure 4 shows the substantial effect that FC- and P-rank-
ing based gene selection methods have on cross-platform
POG. Similar to inter-site comparisons, P-ranking results
in much lower cross-platform POG than FC-ranking.
When FC is used to rank DEGs from each platform, the
cross-platform POG is around 70–85%, depending on the
platform pair. The platforms themselves contribute about
15% differences in the cross-platform POG, as seen from
the spread of the blue POG lines. Noise filtering improves
FC-ranking based cross-platform POG by about 5–10%
and results in more stable POG when a smaller number of
genes are selected (Figure 4b). Importantly, the relative
differences between FC- and P-ranking methods remain
the same after filtering.
Concordance between microarray and TaqMan® assays
TaqMan® real-time PCR assays are widely used to validate
microarray results [37,38]. In the MAQC project, the
expression levels of 997 genes randomly selected from
available TaqMan® assays have been quantified in the four
MAQC samples [13,39]. Nine hundred and six (906) of
the 997 genes are among the "12,091" set of genes found
on all of the six genome-wide microarray platforms [13].
There are four technical replicates for each sample and the
DEGs for TaqMan® assays were identified using the same
Concordance for inter-site comparison with samples C and D Figure 3
Concordance for inter-site comparison with samples C and D. The largest fold change between samples C and D is small 
(three-fold). For each platform, DEG lists from sites 1 and 2 are compared. Analyses are performed using the subset of genes 
that are commonly detectable by the two test sites.BMC Bioinformatics 2008, 9(Suppl 9):S10 http://www.biomedcentral.com/1471-2105/9/S9/S10
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six gene selection procedures as those used for microarray
data. The DEGs calculated from the microarray data are
compared with DEGs calculated from TaqMan® assay data.
With noise filtering (i.e., focusing on the genes detected by
both the microarray platform and TaqMan®  assays),
80–85% concordance was observed (Figure 5). Consistent
with inter-site and cross-platform comparisons, POGs
comparing microarray with TaqMan® assays also show
that ranking genes by FC results in markedly higher POG
than ranking by P alone, especially for short gene lists.
POG results without noise filtering (Figure 6) are some
5% lower but the notable differences in POG between the
FC- and P-ranking are unchanged.
Reproducibility of FC and t-statistic: different metrics for 
identifying differentially expressed genes (DEGs)
Figure 7 shows that the inter-site reproducibility of log2
FC (panel a) is much higher than that of log2 t-statistic
(panel b). In addition, the relationship between log2 FC
and log2 t-statistic from the same test site is non-linear
and the correlation appears to be low (panel c). We see
similar results when data from different microarray plat-
forms are compared to each other or when microarray
data are compared against TaqMan® assay data (results not
shown). The differences between the reproducibility of FC
and t-statistic observed here are consistent with the differ-
ences between POG results in inter-site (Figures 1, 2, 3),
cross-platform (Figure 4), and microarray versus TaqMan®
assay (Figures 5 and 6) comparisons. The nonlinear rela-
tionship between log2 FC and log2 t-statistic (Figure 7c)
leads to low concordance between the list of DEGs
Concordance for cross-platform comparisons Figure 4
Concordance for cross-platform comparisons. Panel a: Based on the data set of "12,091" genes (without noise filtering); Panel 
b: Based on subsets of genes commonly detected ("Present") by two platforms. For each platform, the data from test site1 are 
used for cross-platform comparison. Each POG line corresponds to comparison of the DEGs from two microarray platforms 
using one of the six gene selection methods. There are ten platform-platform comparison pairs, resulting in 60 POG lines for 
each panel. The x-axis represents the number of selected DEGs, and the y-axis is the percentage (%) of genes common to the 
two gene lists derived from two platforms at a given number of DEGs. POG lines circled by the blue oval are from FC based 
gene selection methods with or without a P cutoff, whereas POG lines circled by the teal oval are from P based gene selection 
methods with or without an FC cutoff. Shown here are results for comparing sample B and sample A.BMC Bioinformatics 2008, 9(Suppl 9):S10 http://www.biomedcentral.com/1471-2105/9/S9/S10
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derived from FC-ranking and the list derived from t-statis-
tic (P) ranking (Figure 8); an expected outcome due to the
different emphases of FC and P.
Joint FC and P rule illustrated with a volcano plot: ranking 
by FC, not by P
Figure 9 is a volcano plot depicting how a joint FC and P
rule works in gene selection. It uses the MAQC Agilent
data, and plots negative log10 P on the y-axis versus log2
FC on the x-axis. A joint rule chooses genes that fall in the
upper left and upper right sections of the plot (sections A
and C of Figure 9). Other possible cutoff rules for combin-
ing FC and P are apparent, but are precluded from inclu-
sion due to space. An important conclusion from this
study is that genes should be ranked and selected by FC (x-
axis) with a non-stringent P threshold in order to generate
reproducible lists of DEGs. The more stringent the P-value
threshold, the less reproducible the DEG list is. Our
results provide practical guidance to choose the appropri-
ate FC and P-value cutoffs in using the "volcano plots" to
select DEGs.
Concordance using other statistical tests
Numerous different statistical tests including rank tests
(e.g., Wilcoxon rank-sum test) and shrunken t-tests (e.g.,
SAM) have been used for the identification of DEGs.
Although this work is not intended to serve as a compre-
hensive performance survey of different statistical proce-
Concordance between microarray and TaqMan® assays Figure 5
Concordance between microarray and TaqMan® assays. Each panel represents the comparison of one microarray platform to 
TaqMan® assays. For each microarray platform, the data from test site 1 are used for comparison to TaqMan® assays. Each 
POG line corresponds to comparison of the DEGs from one microarray platform and those from the TaqMan® assays using 
one of the six gene selection methods. The x-axis represents the number of selected DEGs, and the Y-axis is the percentage 
(%) of genes common to DEGs derived from a microarray platform and those from TaqMan® assays. Shown here are results 
for comparing sample B and sample A using a subset of genes that are detectable by both the microarray platform and Taq-
Man® assays. Results based on the entire set of 906 genes are provided in Figure 6.
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dures, we set out to briefly examine a few examples due to
their popularity. Figure 10 shows the POG results of sev-
eral commonly used approaches including FC-ranking, t-
test statistic, Wilcoxon rank-sum test, and SAM using AFX
site-site comparison as an example[13]. The POG by SAM
(pink line), although greatly improved over that of simple
t-test statistic (purple line), approached, but did not
exceed, the level of POG based on FC-ranking (green
line). In addition, the small numbers of replicates in this
study rendered many ties in the Wilcoxon rank statistic,
resulting in poor inter-site concordance in terms of rank-
order of the DEGs between the two AFX test sites. Similar
findings (data not shown) were observed using the toxi-
cogenomics data set of Guo et al. [21].
Gene selection in simulated datasets
The MAQC data, like data from actual experiments, allows
evaluation of DEG list reproducibility, but not of truth.
Statistics are used to estimate truth, often in terms of sen-
sitivity and specificity, but the estimates are based on
assumptions about data variance and error structure that
are also unknown. Simulations where truth can be speci-
fied a priori are useful to conduct parametric evaluations
of gene selection methods, and true false positives and
negatives are then known. However, results are sensitive
to assumptions regarding data structure and error that for
microarrays remains poorly characterized.
Figure 11 gives POG versus the number of genes for three
simulated data sets (MAQC-simulated set, Small-Delta
simulated set, and Medium-Delta simulated set, see Meth-
ods) that were prepared in order to compare the same
Concordance between microarray and TaqMan® assays without noise-filtering Figure 6
Concordance between microarray and TaqMan® assays without noise-filtering. Each panel represents the comparison of one 
microarray platform to TaqMan® assays. The x-axis represents the number of selected DEGs, and the y-axis is the percentage 
(%) of genes common to DEGs derived from a microarray platform and those from TaqMan® assays. Shown here are results 
for comparing sample B and sample A using the entire set of 906 genes for which TaqMan® assay data are available.
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gene selection methods as the MAQC data. The MAQC-
simulated set was created to emulate the magnitude and
structure of differential expression observed between the
actual MAQC samples A and B (i.e., thousands of genes
with FC > 2). By comparison, the Small-Delta simulated
data set had only 50 significant genes with FC > 2 and
most genes had FC < 1.3. The Medium-Delta data set had
FC profiles in between.
For the MAQC-simulated data, either FC-ranking or FC-
ranking combined with any of the P threshold resulted in
markedly higher POG than any P-ranking method, regard-
less of gene list length and coefficient of variation (CV) of
replicates. The POG is ~100%, ~95%, and ~75%, for rep-
licate CV values of 2%, 10%, and 35% CV, respectively,
decreasing to about 20–30% with an exceedingly high
(100%) CV. In contrast, POG from P-ranking alone varies
from a few percent to only ~10% when 500 genes are
selected.
For the Medium- and Small-Delta simulated data sets, dif-
ferences start to emerge between using FC alone and FC
with P cutoff. From Figure 11, when variances in replicates
become larger (CV > 10%), the reproducibility is greatly
enhanced using FC-ranking with a suitable P cutoff versus
FC or P by themselves. In addition, when variances are
small (CV ≤ 10%), the reproducibility is essentially the
same for FC with P or without. What is clear is that P by
itself did not produce the most reproducible DEG list
under any simulated condition.
Inter-site reproducibility of log2 FC and log2 t-statistic Figure 7
Inter-site reproducibility of log2 FC and log2 t-statistic. a: log2 FC of site 1 versus log2 FC of site 2; b: log2 t-statistic of test site 
1 versus log2 t-statistic of test site 2; and c: log2 FC of test site 1 versus log2 t-statistic of test site 1. Shown here are results for 
comparing sample B and sample A for all "12,091" genes commonly probed by the five microarray platforms. The inter-site 
reproducibility of log2 FC (a) is much higher than that of log2 t-statistic (b). The relationship between log2 FC and log2 t-statis-
tic from the same test site is non-linear and the correlation appears to be low (c).
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Although P-ranking generally resulted in very low POG, a
false positive was rarely produced, even for a list size of
500 (data not shown). Thus, the P criterion performed as
expected, and identified mostly true positives. Unfortu-
nately, the probability of selection of the same true posi-
tives with a fixed P  cutoff in a replicated experiment
appears small due to variation in the P statistic itself (see
inset). FC-ranking by itself resulted in a large number of
false positives with a large number of genes for the
Medium and Small-Delta sets when genes with small FCs
are selected as differentially expressed. These false posi-
tives were greatly reduced to the same level as for the P-
ranking alone when FC-ranking was combined with a P-
cutoff.
Variability of the two-sample t-statistic
In a two-sample t-test comparing the mean of sample A to
the mean of sample B, the t-statistic is given as follows:
where   is the average of the log2 expression levels of
sample A with nA replicates, and   is the average of the
log2 expression levels of sample B with nB replicates, and
Sp
2 = (SSA+SSB)/(nA+nB-2) is the pooled variance of sam-
ples A and B, and SS denotes the sum of squared errors.
The numerator of the t-statistic is the fold-change (FC) in
log2 scale and represents the signal level of the measure-
ments (i.e., the magnitude of the difference between the
expression levels of sample A and sample B). The denom-
inator represents the noise components from the meas-
urements of samples A and B. Thus, the t-statistic
represents a measure of the signal-to-noise ratio. There-
fore, the FC and the t-statistic (P) are two measures for the
differences between the means of sample A and sample B.
The t-statistic is intrinsically less reproducible than FC
when the variance is small.
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Volcano plot illustration of joint FC and P gene selection rule Figure 9
Volcano plot illustration of joint FC and P gene selection rule. 
Genes in sectors A and C are selected as differentially 
expressed. The colors correspond to the negative log10 P and 
log2 fold change values: Red: 20 < -log10 P < 50 and 3 < log2 
fold < 9 or -9 < log2 fold < -3. Blue: 10 < -log10 P < 50 and 2 < 
log2 fold < 3 or -3 < log2 fold < -2. Yellow: 4 < -log10 P < 50 
and 1 < log2 fold < 2 or -2 < log2 fold < -1. Pink : 10 < -log10 P 
< 20 and 3 < log2 fold or log2 fold < -3. Light blue: 4 < -log10 P 
< 10 and 2 < log2 fold or log2 fold < -2. Light green: 2 < -log10 
P < 4 and 1 < log2 fold or log2 fold < -1. Gray)
Concordance between FC and P based gene ranking methods  ("12,091 genes"; test site 1) Figure 8
Concordance between FC and P based gene ranking methods 
("12,091 genes"; test site 1). Each POG line represents a plat-
form using data from its first test site. The x-axis represents 
the number of selected DEGs, and the y-axis is the percent-
age (%) of genes common in the DEGs derived from FC- and 
P-ranking. Shown here are results for comparing sample B 
and sample A for all "12,091" genes commonly probed. 
When a smaller number of genes (up to a few hundreds or 
thousands) are selected, POG for cross selection method 
comparison (FC vs. P) is low. For example, there are only 
about 50% genes in common for the top 500 genes selected 
by FC and P separately, indicating that FC and P rank order 
DEGs dramatically differently. When the number of selected 
DEGs increases, the overlap between the two methods 
increases, and eventually approach to 100% in common, as 
expected. The low concordance between FC- and P-based 
gene ranking methods is not unexpected considering their 
different definitions and low correlation (Figure 7c).
0
10
20
30
40
50
60
70
80
90
100
1 10  8   6   5   4   3   2  100  70   50   40   30   20  1000  700   500   300   200  10000  6000   4000   2000 
Number of differentially expressed genes (2L)
C
o
n
c
o
r
d
a
n
c
e
 
b
e
t
w
e
e
n
 
G
e
n
e
 
L
i
s
t
s
 
S
e
l
e
c
t
e
d
 
b
y
 
F
C
 
a
n
d
 
P
 
(
%
)
AFX
AG1
ILM
GEH
ABIBMC Bioinformatics 2008, 9(Suppl 9):S10 http://www.biomedcentral.com/1471-2105/9/S9/S10
Page 12 of 19
(page number not for citation purposes)
Assume that the data are normally distributed, the vari-
ances of samples A and B are equal (σ2), the numbers of
replicates in samples A and B are equal (n = nA = nB), and
that there is a real difference in the mean values between
samples A and B, d (the true FC in log2 scale). Then the t-
statistic has a non-central t-distribution with non-central
parameter
and the mean and variance of the t-statistic (Johnson and
Kotz, 1970) are
where v = (2n-2) and is the degrees of freedom of the non-
central t-distribution. When d  = 0 (the two means are
equal), then the t-statistic has a t-distribution with mean
E(t) = 0 and Var(t) = v/(v-2). The variance of the t-statistic
depends on the sample size n, the magnitude of the differ-
ence between the two means d, and the variance σ2. On
the other hand, the variance of the mean difference for the
FC is (2/n)σ2. That is, the variance of the FC depends only
on the sample size n and the variance σ2, regardless of the
magnitude of the difference d between the two sample
means.
In an MAQC data set, a typical sample variance for the
log2 expression levels is approximately σ2 = 0.152. With n
= 5, the standard deviation of the FC (in log2 scale) is
0.09. For a differentially expressed gene with a 4-fold
change between 5 replicates of sample A and 5 replicates
of sample B, d = 2 and the t-values have a non-central t-
distribution with (ν = nA+nB-2) = 8 degrees of freedom
and δ = 21.08. From the equations above, the mean and
the variance of the t-values are E(t) = 23.35 and Var(t) =
6.962. Within two standard deviations the expected value
of the t-value ranges from 9.43 (= 23.35-2 × 6.96) to 37.27
(= 23.35+2 × 6.96), corresponding to Ps from 1 × 10-5 to
3 × 10-10, based on the Student's two-sided t-test with 8
degrees of freedom. In contrast, when n = 5 the standard
deviation of the FC (in log2 scale) is 0.09. The expected
value of the FC ranges only from 3.53 (= 21.82) to 4.53 (=
22.18) within two standard deviations. In this case, this
gene would be selected as differentially expressed using
either a FC cutoff of 3.5 or a P cutoff of 1 × 10-5. On the
other hand, for a gene with a 2-fold change (d = 1), the t-
statistic has a non-central t-distribution with δ = 10.54.
The mean and the variance of the t-statistic are E(t) =
11.68 and Var(t) = 3.622 with a corresponding P of 3 × 10-
6 at t = 11.68. Using the same P cutoff, 1 × 10-5, this gene
is likely to be selected with the probability greater than
0.5. For the FC criterion, the expected value of the FC
ranges from 1.76 (= 20.82) to 2.26 (= 21.18). Using the same
FC cutoff of 3.5, this gene is very unlikely to be selected.
Thus, the top ranked gene list based on the FC is more
reproducible than the top ranked gene list based on the P.
The top ranked genes selected by a P cutoff may not be
reproducible between experiments although both lists
may contain mostly differentially expressed genes.
Reference: N. Johnson and S. Kotz (1970). Continuous
Univariate Distributions – 2. Houghton Mifflin, Boston.
Discussion
A fundamental requirement in microarray experiments is
that the identification of DEG lists must be reproducible
if the data and scientific conclusion from them are to be
credible. DEG lists are normally developed by rank-order-
ing genes in accordance with a suitable surrogate value to
represent biological relevance, such as the magnitude of
the differential expression (i.e., FC) or the measure of sta-
tistical significance (P) of the expression change, or both.
The results show that concurrent use of both FC-ranking
and  P-cutoff as criteria to identify biological relevant
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Inter-site concordance based on FC, t-test, Wilcoxon rank- sum test, and SAM Figure 10
Inter-site concordance based on FC, t-test, Wilcoxon rank-
sum test, and SAM. Affymetrix data on samples A and B from 
site 1 and site 2 for the "12,091" commonly mapped genes 
were used[13]. No flagged ("Absent") genes were excluded 
in the analysis. For the Wilcoxon rank-sum tests, there were 
many ties, i.e., many genes exhibited the same level of statisti-
cal significance because of the small sample sizes (five repli-
cates for each group). The tied genes from each test site 
were broken (ranked) by random ordering. Concordance 
between genes selected completely by random choice is 
shown in red and reaches 50% when all candidate genes are 
declared as differentially expressed; the other 50% genes are 
in opposite regulation directions. SAM improves inter-site 
reproducibility compared to t-test, and approaches, but does 
not exceed that of fold-change.
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genes can be essential to attain reproducible DEG lists
across laboratories and platforms.
A decade since the microarray-generated differential gene
expression results of Schena et al[40] and Lockhart et
al[41] were published, microarray usage has become
ubiquitous. Over this time, many analytical techniques
for identifying DEGs have been introduced and used.
Early studies predominantly relied on the magnitude of
differential expression change in experiments done with
few if any replicates, with an FC cutoff typically of two
used to reduce false positives. Mutch et al[42] recom-
mended using intensity-dependent FC cutoffs to reduce
biased selection of genes with low expression.
Gene selection using statistical significance estimates
became more prevalent during the last few years as studies
with replicates became possible. Incorporation of a t-sta-
tistic in gene selection was intended to compensate for the
heterogeneity of variances of genes [43]. Haslett et al. [44]
employed stringent values of both FC and P to determine
DEGs. In recent years, there has been an increasing ten-
dency to use P-ranking for gene selection. Kittleson et al.
[45] selected genes with a FC cutoff of two and a very
restrictive Bonferroni corrected P of 0.05 in a quest for a
short list of true positive genes. Tan et al. [46] used P to
rank genes. Correlation coefficient, which behaves simi-
larly to the t-statistic, has also been widely used as a gene
selection method in the identification of signature genes
for classification purposes [15,47,48].
Gene selection and percentage of agreement in gene lists in simulated data sets Figure 11
Gene selection and percentage of agreement in gene lists in simulated data sets. Illustrations of the effect of biological context, 
replicate CV distribution, gene list size, and gene selection rules/methods on the reproducibility of gene lists using simulated 
microarray data. In some sense, these three graphs represent some extremes as well as typical scenarios in differential expres-
sion assays. However, FC sorting with low P thresholds (0.001 or 0.0001; light and medium gray boxes) consistently performed 
better overall than the other rules, even when FC-ranking or P-ranking by itself did not perform as well.BMC Bioinformatics 2008, 9(Suppl 9):S10 http://www.biomedcentral.com/1471-2105/9/S9/S10
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New and widely employed methods have appeared in
recent years and implicitly correct for the large variance in
the t-statistic that results when gene variance is estimated
with a small number of samples. Allison et al. [16] collec-
tively described these methods as "variance shrinkage"
approaches. They include the popular permutation-based
"SAM" procedure [5,12,49,50], Bayesian-based
approaches [43,51] and others [52]. Qin et al. [34] com-
pared several variance shrinkage methods with a simple t-
statistic and FC for spike-in gene identification on a two-
color platform, concluding that all methods except P per-
formed well. All these methods have the effect of reducing
a gene's variance to be between the average for the sam-
ples, and the average over the arrays.
In some cases, however, the use of FC for gene selection
was criticized and entirely abandoned. For example, Cal-
low et al. [53], using P alone for identifying DEGs, con-
cluded that P alone eliminated the need for filtering low
intensity spots because the t-statistic is uniformly distrib-
uted across the entire intensity range. Reliance on P alone
to represent a gene's FC and variability in gene selection
has become commonplace. Norris and Kahn [54] describe
how false discovery rate (FDR) has become so widely used
as to constitute a standard to which microarray analyses
are held. However, FDR usually employs a shrunken t-sta-
tistic and genes are ranked and selected similar to P (see
Figure 11).
Prior to MAQC, Irizarry et al. [55] compared data from
five laboratories and three platforms using the CAT plots
that are essentially the same as the POG graphs used in
our study. Lists of less than 100 genes derived from FC-
ranking showed 30 to 80% intra-site, inter-site, and inter-
platform concordance. Interestingly, important disagree-
ments were attributable to a small number of genes with
large FC that they posit resulted from a laboratory effect
due to inexperienced technicians and sequence-specific
effects where some genes are not correctly measured.
Exactly how to best employ FC with P to identify genes is
a function of both the nature of the data, and the inevita-
ble tradeoff between sensitivity and specificity that is
familiar across research, clinical screening and diagnos-
tics, and even drug discovery. But how the tradeoff is
made depends on the application. Fewer false negatives at
the cost of more false positives may be desirable when the
application is identifying a few hundred genes for further
study, and FC-ranking with a non-stringent P value cutoff
from a simple t-test could be used to eliminate some
noise. The gene list can be further evaluated in terms of
gene function and biological pathway data, as illustrated
in Guo et al. [21] for toxicogenomic data. Even for rela-
tively short gene lists, FC-ranking together with a non-
stringent P cutoff should result in reproducible lists. In
addition, DEG lists identified by the ranking of FC is
much less susceptible to the impact of normalization
methods. In fact, global scaling methods (e.g., median- or
mean-scaling) do not change the relative ranking of genes
based on FC; they do, however, impact gene ranking by P-
value [21].
The tradeoffs between reproducibility, sensitivity, and
specificity become pronounced when genes are selected
by P alone without consideration of FC, especially when a
stringent P cutoff is used to reduce false positives. When
sample numbers are small, any gene's t-statistic can
change considerably in repeated studies within or across
laboratories or across platforms. Each study can select dif-
ferent significant genes, purely by chance. It is entirely
possible that separately determined lists will have a small
proportion of common genes even while each list com-
prises mostly true positives. This apparent lack of repro-
ducibility of the gene lists is an expected outcome of
statistical variation in the t-statistic for small numbers of
sample replicates. In other words, each study fails to pro-
duce some, but not all, of the correct results. The side box
provides a numerical example of how gene list discord-
ance can result from variation in the t-statistic across stud-
ies. Decreasing the P cutoff will increase the proportion of
true positives, but also diminish the number of selected
genes, diminish genes common across lists, and increase
false negatives. Importantly, selecting genes based on a
small P cutoff derived from a simple t-test without consid-
eration of FC renders the gene list non-reproducible.
Additional insight is gained by viewing gene selection
from the perspective of the biologist ultimately responsi-
ble for interpreting microarray results. Statistically speak-
ing, a microarray experiment tests 10,000 or more null
hypotheses where essentially all genes have non-zero dif-
ferential expression. Statistical tests attempt to account for
an unknowable error structure, in order to eliminate the
genes with low probability of biological relevance. To the
biologist, however, the variance of a gene with a large FC
in one microarray study may be irrelevant if a similar
experiment again finds the gene to have a large FC; the sec-
ond experiment would probably be considered a validat-
ing reproduction. This conclusion would be reasonable
since the gene's P depends on a poor estimate of variance
across few samples, whereas a repeated FC measurement
is tangible reproducibility which tends to increase demon-
strably with increasing FC. The biological interpreter can
also consider knowledge of gene function and biological
pathways before finally assigning biological relevance,
and will be well aware that either P or FC is only another
indicator regarding biological significance.
This study shows that genes with smaller expression fold
changes generated from one platform or laboratory are, inBMC Bioinformatics 2008, 9(Suppl 9):S10 http://www.biomedcentral.com/1471-2105/9/S9/S10
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general, less reproducible in another laboratory with the
same or different platforms. However, it should be noted
that genes with small fold changes may be biologically
important [56]. When a fixed FC cutoff is chosen, sensitiv-
ity could be sacrificed for reproducibility. Alternatively,
when a high P cutoff (or no P cutoff) is used, specificity
could be sacrificed for reproducibility. Ultimately, the
acceptable trade-off is based on the specific question
being asked or the need being addressed. When searching
for a few reliable biomarkers, high FC and low P cutoffs
can be used to produce a highly specific and reproducible
gene list. When identifying the components of genetic
networks involved in biological processes, a lower FC and
higher P cutoff can be used to identify larger, more sensi-
tive but less specific, gene lists. In this case, additional bio-
logical information about putative gene functions can be
incorporated to identify reliable gene lists that are specific
to the biological process of interest.
Truly differentially expressed genes should be more likely
identified as differentially expressed by different plat-
forms and from different laboratories than those genes
with no differential expression between sample groups. In
the microarray field, we usually do not have the luxury of
knowing the "truth" in a given study. Therefore, it is not
surprising that most microarray studies and data analysis
protocols have not been adequately evaluated against the
"truth". A reasonable surrogate of such "truth" could be
the consensus of results from different microarray plat-
forms, from different laboratories using the same plat-
form, or from independent methods such as TaqMan®
assays, as we have extensively explored in this study.
The fundamental scientific requirement of reproducibility
is a critical dimension to consider along with balancing
specificity and sensitivity when defining a gene list. Irre-
producibility would render microarray technology gener-
ally, and any research result, specifically, vulnerable to
criticism. New methods for the identification of DEGs
continue to appear in the scientific literature. These meth-
ods are typically promoted in terms of improved sensitiv-
ity (power) while retaining nominal rates of specificity.
However, reproducibility is seldom emphasized.
Conclusion
The results show that selecting DEGs based solely on P
from a simple t-test most often predestines a poor con-
cordance in DEG lists, particularly for small numbers of
genes. In contrast, using FC-ranking in conjunction with a
non-stringent P-cutoff results in more concordant gene
lists concomitant with needed reproducibility, even for
fairly small numbers of genes. Moreover, enhanced repro-
ducibility holds for inter-site, cross-platform, and
between microarray and TaqMan® assay comparisons, and
is independent of platforms, sample pairs, and normaliza-
tion methods. The results should increase confidence in
the reproducibility of data produced by microarray tech-
nology and should also expand awareness that gene lists
identified solely based on P will tend to be discordant.
This work demonstrates the need for a shift from the com-
mon practice of selecting differentially expressed genes
solely on the ranking of a statistical significance measure
(e.g., t-statistic) to an approach that emphasizes fold-
change, a quantity actually measured by microarray tech-
nology.
Conclusions and recommendations
1. A fundamental step of microarray studies is the identi-
fication of a small subset of DEGs from among tens of
thousands of genes probed on the microarray. DEG lists
must be concordant to satisfy the scientific requirement of
reproducibility, and must also be specific and sensitive for
scientific relevance. A baseline practice is needed for prop-
erly assessing reproducibility/concordance alongside spe-
cificity and sensitivity.
2. Reports of DEG list instability in the literature are often
a direct consequence of comparing DEG lists derived from
a simple t-statistic when the sample size is small and var-
iability in variance estimation is large. Therefore, the prac-
tice of using P  alone for gene selection should be
discouraged.
3. A DEG list should be chosen in a manner that concur-
rently satisfies scientific objectives in terms of inherent
tradeoffs between reproducibility, specificity, and sensi-
tivity.
4. Using FC and P together balances reproducibility, spe-
cificity, and sensitivity. Control of specificity and sensitiv-
ity can be accomplished with a P  criterion, while
reproducibility is enhanced with an FC criterion. Sensitiv-
ity can also be improved by better platforms with greater
dynamic range and lower variability or by increased sam-
ple sizes.
5. FC-ranking should be used in combination with a non-
stringent P threshold to select a DEG list that is reproduc-
ible, specific, and sensitive, and a joint rule is recom-
mended as a baseline practice.
Methods
MAQC data sets
The MAQC data sets analyzed in this study are available
from GEO under series accession number GSE5350. Anal-
yses identified differentially expressed genes between the
primary samples A (Stratagene Universal Human Refer-
ence RNA, Catalog #740000) and B (Ambion Human
Brain Reference RNA, Catalog #6050) of the MAQC study.
Analyses are additionally limited to data sets from the fol-BMC Bioinformatics 2008, 9(Suppl 9):S10 http://www.biomedcentral.com/1471-2105/9/S9/S10
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lowing five commercial genome-wide microarray plat-
forms: ABI (Applied Biosystems), AFX (Affymetrix), AG1
(Agilent one-color), GEH (GE Healthcare), and ILM (Illu-
mina), and to the subset of "12,091" genes commonly
probed by them. TaqMan® assay data for 906 genes are
used to examine gene list comparability between microar-
rays and TaqMan® assays. For more information about the
MAQC project and the data sets, refer to Shi et al [13].
Normalization methods
The following manufacturer's preferred normalization
methods were used: quantile normalization for ABI and
ILM, PLIER for AFX, and median-scaling for AG1 and GEH
[13]. For quantile normalization (including PLIER), each
test site is independently considered.
Gene ranking (selection) rules
Six gene ranking (selection) methods were examined: (1)
FC (fold change ranking); (2) FC_P0.05 (FC-ranking with
P cutoff of 0.05); (3) FC_P0.01 (FC-ranking with P cutoff
of 0.01); (4) P (P-ranking, simple t-test assuming equal
variance); (5) P_FC2 (P-ranking with FC cutoff of 2); (6)
P_FC1.4 (P-ranking with FC cutoff of 1.4). When a cutoff
value (e.g., P < 0.05) is imposed for a ranking metric (e.g.,
FC), it is likely that the lists of candidate genes that meet
the cutoff value may not be the same for the two test sites
or two platforms as a result of differences in inter-site or
cross-platform variations. Such differences are part of the
gene selection process and have been carried over to the
gene ranking/selection stage.
Evaluation criterion – POG (percentage of overlapping 
genes)
The POG (percentage of overlapping genes) calculation
[11,13] was applied in three types of comparisons: (1)
Inter-site comparison using data from the three test sites
of each platform; (2) Cross-platform comparison between
ABI, AFX, AG1, GEH, and ILM using data from test site 1;
for each sample pair, there are ten cross-platform pairs for
comparison; (3) Microarray versus TaqMan® assay com-
parisons.
POG is calculated for many different cutoffs that can be
considered as arbitrary.
The number of genes considered as differentially
expressed is denoted as 2L, where L is both the number of
genes up- and down-regulated. The number of genes
available for ranking and selection in one direction, L, var-
ies from 1 to 6000 (with a step of one) or when there are
no more genes in one regulation direction, corresponding
to 2L varying from 2 to 12,000. Directionality of gene reg-
ulation is considered in POG calculations; genes selected
by two sites or platforms but with different regulation
directionalities are considered as discordant. Therefore,
POG can hardly reach 100% in reality.
The formula for calculating POG is: POG =
100*(DD+UU)/2L, where DD and UU are the number of
commonly down- or up-regulated genes, respectively,
from the two lists, and L is the number of genes selected
from the up- or down-regulation directionality. To over-
come the confusion of different numbers for the denomi-
nator, in our POG calculations we deliberately selected an
equal number of up-regulated and down-regulated genes,
L [11]. The POG graphs shown in this study are essentially
the same as the CAT (correspondence at the top) plots
introduced by Irizarry et al. [55] and the POG graphs that
we introduced previously [11] except that in the current
POG graphs the x-axis is in log-scale to emphasize the
details when fewer genes are selected.
Noise-filtering
Most of the analyses in this study exclude flagging infor-
mation; that is, the entire set of "12,091" genes is used in
the analyses. Some calculations are limited to subsets of
genes commonly detectable ("common present") by the
two test sites or two platforms under comparison. To be
denoted as "commonly present", the gene is detected
("present") in the majority of replicates (e.g., three or
more when there are five replicates) for each sample in a
sample-pair comparison and for each test site or platform.
Gene selection simulation
A simulation was created to emulate the characteristics of
the MAQC dataset. Fifteen thousand simulated genes were
created where 5,000 were undifferentiated in expression
between simulated biological samples A and B and
10,000 were differentiated but at various levels (exponen-
tial distribution for the log FC, where almost 4,000 are dif-
ferentiated two-fold or higher, similar to a typical
platform in the MAQC study, divided equally into up and
down regulated genes). To simulate instances of technical
or biological replicates, multiplicative noise (error) was
added to the signal for each gene for each of five simulated
replicates for each sample using an error distribution that
would produce a replicate CV similar to that typically seen
in the MAQC data set (i.e., the mean replicate CV would
be roughly 10%). The CV for any given gene was ran-
domly selected from a trimmed exponential distribution.
To address a variety of additional error scenarios but pre-
serving the same distribution of fold change, we also con-
sidered three additional mean CV values (2%, 35%, and
100%). To understand the impact of gene list size on the
stability of the DEG list, list sizes of 10, 25, 100, and 500
genes were examined for each mean CV scenario. Several
gene selection rules were compared: FC-ranking only, P-
ranking only, and shrunken t-statistic ranking. Note: P-
ranking is equivalent to t-statistic ranking as well as rank-BMC Bioinformatics 2008, 9(Suppl 9):S10 http://www.biomedcentral.com/1471-2105/9/S9/S10
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ing based on FDR that monotonically transforms the P-
value. In addition, shrunken t-statistic ranking is equiva-
lent to ranking based on the test statistic used by SAM and
related methods. In addition, rules based on FC-ranking
with a P threshold were also compared (for P = 0.1, 0.01,
0.001, and 0.0001). Finally, to simulate differences in the
variation patterns of analytes between platforms and even
between laboratories, covariance between laboratories/
platforms of the variance for each gene was included in
the simulations. For a given mean CV, 20 or more simu-
lated instances of five replicates of simulated biological
samples A and B were created and DEG lists were prepared
for each instance that were rank ordered using the meth-
ods described above. To determine reproducibility of a
given method for a given mean CV under a given gene list
size, the rank-ordered gene lists from these 20 instances
were pair-wise compared for consistency and reproduci-
bility. The results presented in the graphs are averages
from those pair-wise comparisons.
The MAQC actual data is characterized by large magni-
tudes of differential expression among the vast majority of
the 12,091 common genes, with some 4000 exhibiting FC
> 2 and hundreds with FC > 10. As such, the data may be
atypical of commonplace microarray experiments with
biological effects. Consequently, two other simulation
data sets were created with far fewer genes with large FC,
as might be expected in some actual microarray experi-
ments. Specifically, the Small-Delta data set was created
with fewer than 50 genes with FC > 2, and a FC < 1.3 for
most differentiated genes, and 10,000 undifferentiated
genes. In addition, the variances of the genes were corre-
lated similar to that observed in the MAQC data. The third
simulated dataset, termed the Medium-Delta set, had a
large number of differentiated genes similar to the MAQC
simulated dataset, but with small FC similar to the Small-
Delta set. Again, gene variances were correlated similar to
that observed in the MAQC data.
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